

## Appointment of Lewis Utting to Advisory Board

### Highlights:

- Mr Lewis Utting appointed to newly created ECT Advisory Board
- Mr Utting has over 20 years' experience in the chemical industry, water treatment and mineral processing sectors and was a former BASF minerals processing and specialty chemicals executive
- Mr Utting served as CEO and Managing Director of SciDev (ASX:SDV), where he led the company's transformation and established the first PFAS remediation business on the ASX through strategic acquisition and commercialisation of PFAS-management technologies
- Mr Utting joins Robert Bilott and Professor James Tour as part of the Company's Advisory Board, further strengthening the Company's commercial and technical capability
- Establishment of the ECT Advisory Board and recruitment of key members places ECT in a strong position to execute on its newly established growth strategy of developing a diversified portfolio of high-impact and disruptive technologies, such as its PFAS remediation solution, in collaboration with renowned researchers and industry leaders

Environmental Clean Technologies Limited (**ASX: ECT**) (**ECT** or **the Company**) is pleased to announce the appointment of Mr Lewis Utting to its Advisory Board. Mr Utting is a highly accomplished business executive and leader and boasts more than two decades of experience across the chemical, water treatment and mineral processing sectors.

As the CEO and Managing Director of SciDev, Mr Utting was instrumental in building the company into the first Per- and Polyfluoroalkyl Substances (PFAS) remediation business on the Australian Securities Exchange, commercialising advanced water-treatment and emerging PFAS-management technologies.

Prior to joining SciDev, Mr Utting held senior roles at multinational chemical company BASF, where he worked across specialty chemicals and mineral-processing solutions. He has authored and co-authored several technical papers and is an inventor on a patent application relating to tailings (mining waste) disposal. Mr Utting brings a strong global commercial network and proven record of scaling industrial technologies, developing new market opportunities, and forming strategic partnerships across the mining, chemicals, infrastructure and environmental services markets.

**Commenting on the appointment of Mr Utting, ECT Executive Chairman, Faldi Ismail, said, "We are delighted to welcome Lewis to the ECT Advisory Board. His deep expertise spanning the chemical industry, water treatment, PFAS remediation, and mineral processing brings highly relevant and valuable strategic capability as we advance into the next phase of our development.**



*“Having someone with Lewis’s calibre of ASX and market experience join ECT is a tremendous advantage as we progress the commercialisation of our remediation technology. His extensive background, proven leadership, and breadth of industry insight make him an outstanding appointment and a significant addition to our Advisory Board.*

*“ECT is setting the right foundation and building an industry leading team to ensure the Company can deliver on a busy and transformative 2026 and execute its growth strategy to develop a portfolio of high-impact and disruptive technologies across high-growth sectors, in collaboration with renowned researchers”*

In connection with his appointment to the Advisory Board, the Company will issue Mr Utting a total of 3,500,000 performance rights, which will vest and convert into fully paid ordinary ECT shares as per the below Schedule.

The Board authorises the release of this announcement.

**For further information, please contact:**

**INVESTORS**

Faldi Ismail  
Chairman

info@ectltd.com.au / +613 9849 6203

Stephanie Richardson  
Sodali & Co

stephanie.richardson@sodali.com / +61 423 459 440

**Forward-looking Statement**

This announcement may contain forward-looking statements regarding future events or performance, including but not limited to projections of financial results, anticipated growth, and business strategies. These forward-looking statements are based on current expectations, assumptions, and projections that involve inherent risks and uncertainties. Actual results may differ materially from those anticipated due to various factors, including market conditions, regulatory changes, technological advancements, and economic conditions.

Investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.

Investors should carefully consider the risks and uncertainties disclosed in the Company's periodic reports filed with the Australian Securities Exchange (ASX) and other regulatory authorities. Forward-looking statements are provided as of the date of this announcement, and the Company disclaims any obligation to update them, except as required by law



## SCHEDULE

In connection with his appointment to the Advisory Board, the Company will issue to Mr Utting, solely in his individual capacity as an Advisory Board member a total of 3,500,000 performance rights, which will vest and convert into fully paid ordinary ECT shares as follows:

- 1,000,000 will vest if Mr Utting remains on the Advisory Board for one year;
- 1,000,000 will vest if Mr Utting remains on the Advisory Board for two years;
- 750,000 will vest if ECT's share price reaches a 10 day VWAP of 50c at any time within two years from grant (and Mr Utting remains on the Advisory Board at that time); and
- 750,000 will vest if ECT's share price reaches a 10 day VWAP of \$1 at any time within three years from grant (and Mr Utting remains on the Advisory Board at that time).